Andrew Gu's most recent trade in Cellectar Biosciences Inc was a trade of 25,000 Stock option (right to buy) done . Disclosure was reported to the exchange on July 7, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cellectar Biosciences Inc | Andrew Gu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2026 | 25,000 | 25,000 | - | - | Stock option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 06 Jul 2026 | 10,000 | 114,395 | - | 5.4 | 53,500 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2026 | 10,000 | 226,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 57.16 per share. | 06 Jul 2026 | 7,913 | 106,482 | - | 57.2 | 452,283 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 57.76 per share. | 06 Jul 2026 | 2,087 | 104,395 | - | 57.8 | 120,553 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Jun 2026 | 10,000 | 114,395 | - | 5.4 | 53,500 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2026 | 10,000 | 236,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 53.00 per share. | 18 Jun 2026 | 10,000 | 104,395 | - | 53 | 530,000 | Common Stock |
| Arbor Realty Trust Inc | Andrew Guziewicz | Chief Credit Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2026 | 12,886 | 110,095 (0%) | 0% | - | Common Stock, par value $0.01 per share | |
| Arbor Realty Trust Inc | Andrew Guziewicz | Chief Credit Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.67 per share. | 13 Mar 2026 | 1,549 | 108,546 (0%) | 0% | 7.7 | 11,881 | Common Stock, par value $0.01 per share |
| Arbor Realty Trust Inc | Andrew Guziewicz | Chief Credit Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.67 per share. | 13 Mar 2026 | 976 | 107,570 (0%) | 0% | 7.7 | 7,486 | Common Stock, par value $0.01 per share |
| Arbor Realty Trust Inc | Andrew Guziewicz | Chief Credit Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.67 per share. | 13 Mar 2026 | 939 | 106,631 (0%) | 0% | 7.7 | 7,202 | Common Stock, par value $0.01 per share |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.32 per share. | 09 Mar 2026 | 1,021 | 104,395 | - | 59.3 | 60,566 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 74,993 | 74,993 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 44,864 | 107,323 | - | 0 | Common Stock | |
| Welltower | Andrew Gundlach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 1,787 | 1,787 | - | - | Other Stock Unit | |
| Welltower | Andrew Gundlach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 1,787 | 1,787 | - | - | LTIP Units | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 61.98 per share. | 26 Feb 2026 | 1,009 | 105,416 | - | 62.0 | 62,538 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 61.98 per share. | 26 Feb 2026 | 898 | 106,425 | - | 62.0 | 55,658 | Common Stock |
| Caribou Biosciences Inc | Andrew L. Guggenhime | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2026 | 45,000 | 45,000 | - | - | Option to purchase Common Stock | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Jan 2026 | 61,850 | 62,459 | - | 0 | Common Stock | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Jan 2026 | 61,850 | 61,850 | - | 0 | Common Stock | |
| Welltower | Andrew Gundlach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 49 | 49 | - | - | Other Stock Unit | |
| Welltower | Andrew Gundlach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 49 | 49 | - | - | LTIP Units | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.41 per share. | 08 Sep 2025 | 2,890 | 124,309 | - | 32.4 | 93,665 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 02 Sep 2025 | 2,381 | 128,628 | - | 31.6 | 75,144 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 02 Sep 2025 | 1,429 | 127,199 | - | 31.6 | 45,099 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 02 Sep 2025 | 1,270 | 131,009 | - | 31.6 | 40,081 | Common Stock |
| Welltower | Andrew Gundlach | Director | Purchase of securities on an exchange or from another person at price $ 151.46 per share. | 30 Jun 2025 | 10,000 | 20,000 (0%) | 0% | 151.5 | 1,514,600 | Common Stock |
| Welltower | Andrew Gundlach | Director | Purchase of securities on an exchange or from another person at price $ 151.46 per share. | 30 Jun 2025 | 10,000 | 10,000 (0%) | 0% | 151.5 | 1,514,600 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.93 per share. | 07 Apr 2025 | 4,777 | 131,950 | - | 20.9 | 99,983 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 4,777 | 121,115 | - | - | Stock Option (right to buy) | |
| Arbor Realty Trust Inc | Andrew Guziewicz | Chief Credit Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 8,123 | 100,167 (0%) | 0% | - | Common Stock, par value $0.01 per share | |
| Arbor Realty Trust Inc | Andrew Guziewicz | Chief Credit Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.41 per share. | 14 Mar 2025 | 1,044 | 97,209 (0%) | 0% | 12.4 | 12,956 | Common Stock, par value $0.01 per share |
| Arbor Realty Trust Inc | Andrew Guziewicz | Chief Credit Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.31 per share. | 14 Mar 2025 | 976 | 99,191 (0%) | 0% | 12.3 | 12,015 | Common Stock, par value $0.01 per share |
| Arbor Realty Trust Inc | Andrew Guziewicz | Chief Credit Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.31 per share. | 14 Mar 2025 | 938 | 98,253 (0%) | 0% | 12.3 | 11,547 | Common Stock, par value $0.01 per share |
| Welltower | Andrew Gundlach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 2,427 | 2,427 | - | - | LTIP Units | |
| Welltower | Andrew Gundlach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 2,427 | 2,427 | - | - | Other Stock Unit | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 75,991 | 75,991 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 22,761 | 132,252 | - | 0 | Common Stock | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.10 per share. | 27 Feb 2025 | 3,809 | 127,173 | - | 72.1 | 274,629 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.02 per share. | 27 Feb 2025 | 1,270 | 130,982 | - | 73.0 | 92,735 | Common Stock |
| Caribou Biosciences Inc | Andrew L. Guggenhime | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 40,500 | 40,500 | - | - | Option to purchase Common Stock | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Feb 2025 | 8,000 | 117,491 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 8,000 | 246,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 83.64 per share. | 18 Feb 2025 | 6,182 | 111,309 | - | 83.6 | 517,056 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 84.58 per share. | 18 Feb 2025 | 1,818 | 109,491 | - | 84.6 | 153,766 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 21 Jan 2025 | 8,000 | 117,491 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2025 | 8,000 | 254,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 86.08 per share. | 21 Jan 2025 | 5,318 | 112,173 | - | 86.1 | 457,795 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 87.25 per share. | 21 Jan 2025 | 1,999 | 110,174 | - | 87.2 | 174,407 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 87.70 per share. | 21 Jan 2025 | 683 | 109,491 | - | 87.7 | 59,899 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2024 | 8,000 | 262,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew Guggenhime L. | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Dec 2024 | 8,000 | 117,491 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | L. Guggenhime Andrew | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 88.70 per share. | 18 Dec 2024 | 3,373 | 112,928 | - | 88.7 | 299,188 | Common Stock |
| Vaxcyte Inc | Guggenhime Andrew L. | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 89.31 per share. | 18 Dec 2024 | 3,157 | 109,771 | - | 89.3 | 281,958 | Common Stock |
| Vaxcyte Inc | L. Guggenhime Andrew | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 87.26 per share. | 18 Dec 2024 | 1,190 | 116,301 | - | 87.3 | 103,835 | Common Stock |
| Vaxcyte Inc | Guggenhime Andrew L. | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 90.24 per share. | 18 Dec 2024 | 280 | 109,491 | - | 90.2 | 25,267 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Nov 2024 | 8,000 | 117,491 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 8,000 | 270,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 85.59 per share. | 18 Nov 2024 | 6,111 | 111,380 | - | 85.6 | 523,071 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 86.49 per share. | 18 Nov 2024 | 1,757 | 109,623 | - | 86.5 | 151,956 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 87.05 per share. | 18 Nov 2024 | 132 | 109,491 | - | 87.1 | 11,491 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2024 | 87,481 | 87,481 | - | - | Performance Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2024 | 35,661 | 35,661 | - | - | Performance Restricted Stock Units | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2024 | 19,108 | 125,892 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.93 per share. | 25 Oct 2024 | 19,108 | 109,491 | - | 20.9 | 399,930 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 115.26 per share. | 18 Oct 2024 | 36,114 | 96,269 | - | 115.3 | 4,162,608 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 14,000 | 278,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Oct 2024 | 14,000 | 132,383 | - | 5.4 | 74,900 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 12,000 | 292,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Oct 2024 | 12,000 | 118,383 | - | 5.4 | 64,200 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Oct 2024 | 8,000 | 98,383 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 8,000 | 304,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 8,000 | 312,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Oct 2024 | 8,000 | 106,383 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 116.19 per share. | 18 Oct 2024 | 5,886 | 90,383 | - | 116.2 | 683,900 | Common Stock |
| Welltower | Andrew Gundlach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 164 | 164 | - | - | LTIP Units | |
| Welltower | Andrew Gundlach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 164 | 164 | - | - | Other Stock Units | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Sep 2024 | 8,000 | 98,383 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2024 | 8,000 | 320,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 115.60 per share. | 18 Sep 2024 | 5,485 | 92,898 | - | 115.6 | 634,052 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 116.29 per share. | 18 Sep 2024 | 1,686 | 91,212 | - | 116.3 | 196,065 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 117.53 per share. | 18 Sep 2024 | 829 | 90,383 | - | 117.5 | 97,433 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 110.15 per share. | 03 Sep 2024 | 6,337 | 90,383 | - | 110.2 | 698,021 | Common Stock |
| Welltower | Andrew Gundlach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 133 | 0 | - | - | Other Stock Units | |
| Welltower | Andrew Gundlach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 133 | 0 | - | - | LTIP Units | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 19 Aug 2024 | 8,000 | 104,720 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 8,000 | 328,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 78.25 per share. | 19 Aug 2024 | 4,994 | 99,726 | - | 78.2 | 390,771 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 79.14 per share. | 19 Aug 2024 | 3,006 | 96,720 | - | 79.1 | 237,880 | Common Stock |
| Welltower | Andrew Gundlach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 1,146 | 0 | - | - | Other Stock Units | |
| Welltower | Andrew Gundlach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 1,146 | 0 | - | - | LTIP Units | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Jul 2024 | 8,000 | 104,720 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jul 2024 | 8,000 | 336,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 80.12 per share. | 18 Jul 2024 | 3,095 | 101,625 | - | 80.1 | 247,956 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 81.06 per share. | 18 Jul 2024 | 2,500 | 99,125 | - | 81.1 | 202,638 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 82.32 per share. | 18 Jul 2024 | 1,479 | 97,646 | - | 82.3 | 121,747 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 83.14 per share. | 18 Jul 2024 | 926 | 96,720 | - | 83.1 | 76,985 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Jun 2024 | 8,000 | 104,720 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2024 | 8,000 | 344,827 | - | - | Stock Option (right to buy) |